Amphotericin B loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): physicochemical and solid-solution state characterizations

References

• Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents. 2006;27:12–16.
   PubMed Web of Science ®Google Scholar
• Hillery AM. Supramolecular lipidic drug delivery systems: from laboratory to clinic. A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B. Adv Drug Deliv Rev. 1997;24:345–363.
   Web of Science ®Google Scholar
• Chapman SW, Cleary JD. Rogers PD. Systemic antifungal drugs: amphotericin B. In: Dismukes WE, Pappas PG, Sobel J, editors. Clinical Mycology. NewYork (NY): Oxford University Press; 2003. p. 33–48.
   Google Scholar
• Halperin A, Shadkchan Y, Pisarevsky E, et al. Novel water-soluble amphotericin B-PEG conjugates with low toxicity and potent in vivo efficacy. J Med Chem. 2016;59:1197–1206.
   PubMed Web of Science ®Google Scholar
• Hartsel S, Bolard J. Amphotericin B: new life for an old drug. Trends Pharmacol Sci. 1996;17:445–449.
   PubMed Web of Science ®Google Scholar
• Ravikumar S, Win MS, Chai LYA. Optimizing outcomes in immunocompromised hosts: understanding the role of immunotherapy in invasive fungal diseases. Front Microbiol. 2015;6:1322.
   PubMed Web of Science ®Google Scholar
• Soliman GM. Nanoparticles as safe and effective delivery systems of antifungal agents: achievements and challenges. Int J Pharm. 2017;523:15–32.
   PubMed Web of Science ®Google Scholar
• Fukui H, Koike T, Saheki A, et al. A novel delivery system for amphotericin B with lipid nano-sphere (LNS®). Int J Pharm. 2003;265:37–45.
   PubMed Web of Science ®Google Scholar
• Arikan S, Rex JH. Lipid-based antifungal agents: current status. Curr Pharm Des. 2001;7:393–415.
   PubMed Web of Science ®Google Scholar
• Espuelas MS, Legrand P, Campanero MA, et al. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. J Antimicrob Chemother. 2003;52:419–427.
   PubMed Web of Science ®Google Scholar
• Moreno MA, Frutos P, Ballesteros MP. Lyophilized lecithin based oil-water microemulsions as a new and low toxic delivery system for amphotericin B. Pharm Res. 2001;18:344–351.
   PubMed Web of Science ®Google Scholar
• Müller RH, Schmidt S, Buttle I, et al. SolEmuls-novel technology for the formulation of i.v. emulsions with poorly soluble drugs. Int J Pharm. 2004;269:293–302.
   PubMed Web of Science ®Google Scholar
• Müller RH, Lippacher A, Gohla S. Solid lipid nanoparticles (SLN) as a carrier system for the controlled release of drugs. In: Wise D, editor. Handbook of pharmaceutical controlled release technology. New York (NY): Marcel Dekker; 2000. p. 377–392.
   Google Scholar
• Souto EB, Wissing SA, Barbosa CM, et al. Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations. Eur J Pharm Biopharm. 2004;58:83–90.
   PubMed Web of Science ®Google Scholar
• Severino P, Andreani T, Macedo AS, et al. current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J Drug Deliv. 2012;2012:750891.
   PubMedGoogle Scholar
• Tan SW, Billa N, Roberts CR, et al. Surfactant effects on the physical characteristics of amphotericin B-containing nanostructured lipid carriers. Colloids Surf A Physicochem Eng Aspects. 2010;372:73–79.
   Web of Science ®Google Scholar
• Bianco MA, Gallarate M, Trotta M, et al. Amphotericin B loaded SLN prepared with the coacervation technique. J Drug Del Sci Tech. 2010;20:187–191.
   Web of Science ®Google Scholar
• Butani D, Yewale C, Misra A. Topical amphotericin B solid lipid nanoparticles: design and development. Colloids Surf B Biointerfaces. 2016;139:17–24.
   PubMed Web of Science ®Google Scholar
• Tan SW, Billa N. Lipid effects on expulsion rate of amphotericin B from solid lipid nanoparticles. AAPS PharmSciTech. 2014;15:287–295.
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165–196.
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131–S155.
   PubMed Web of Science ®Google Scholar
• Bunjes H, Koch MHJ, Westesen K. Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J Pharm Sci. 2003;92:1509–1520.
   PubMed Web of Science ®Google Scholar
• Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res. 2004;21:201–230.
   PubMed Web of Science ®Google Scholar
• Manosroi A, Kongkaneramit L, Manosroi J. Stability and transdermal absorption of topical amphotericin B liposome formulations. Int J Pharm. 2004;270:279–286.
   PubMed Web of Science ®Google Scholar
• Wilkinson JM, McDonald C, Parkin JE, et al. A high-performance liquid-chromatographic assay for amphotericin B in a hydrophilic colloidal paste base. J Pharm Biomed Anal. 1998;17:751–755.
   PubMed Web of Science ®Google Scholar
• Hu F-Q, Jiang S-P, Du Y-Z, et al. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces. 2005;45:167–173.
   PubMed Web of Science ®Google Scholar
• Hamilton-Miller JM. The effect of pH and of temperature on the stability and bioactivity of nystatin and amphotericin B. J Pharm Pharmacol. 1973;25:401–407.
   PubMed Web of Science ®Google Scholar
• Schubert MA, Müller-Goymann CC. Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm. 2005;61:77–86.
   PubMed Web of Science ®Google Scholar
• Patil-Gadhe A, Pokharkar V. Montelukast-loaded nanostructured lipid carriers: part I oral bioavailability improvement. Eur J Pharm Biopharm. 2014;88:160–168.
   PubMed Web of Science ®Google Scholar
• Shete H, Patravale V. Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization. Int J Pharm. 2013;454:573–583.
   PubMed Web of Science ®Google Scholar
• Elbahwy IA, Ibrahim HM, Ismael HR, et al. Enhancing bioavailability and controlling the release of glibenclamide from optimized solid lipid nanoparticles. J Drug Deliv Sci Tech. 2017;38:78–89.
   Web of Science ®Google Scholar
• Raina H, Kaur S, Jindal AB. Development of efavirenz loaded solid lipid nanoparticles: risk assessment, quality-by-design (QbD) based optimisation and physicochemical characterisation. J Drug Deliv Sci Tech. 2017;39:180–191.
   Web of Science ®Google Scholar
• Espuelas S, Legrand P, Irache J, et al. Poly(ε-caprolactone) nanospheres as an alternative way to reduce amphotericin B toxicity. Int J Pharm. 1997;158:19–27.
   Web of Science ®Google Scholar
• Kim Y-T, Shin B-K, Garripelli VK, et al. A thermosensitive vaginal gel formulation with HPgammaCD for the pH-dependent release and solubilization of amphotericin B. Eur J Pharm Sci. 2010;41:399–406.
   PubMed Web of Science ®Google Scholar
• Zu Y, Sun W, Zhao X, et al. Preparation and characterization of amorphous amphotericin B nanoparticles for oral administration through liquid antisolvent precipitation. Eur J Pharm Sci. 2014;53:109–117.
   PubMed Web of Science ®Google Scholar
• Kakkar V, Singh S, Singla D, et al. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res. 2011;55:495–503.
   PubMed Web of Science ®Google Scholar
• Westesen K, Siekmann B, Koch MHJ. Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int J Pharm. 1993;93:189–199.
   Web of Science ®Google Scholar
• Schubert MA, Schicke BC, Müller-Goymann CC. Thermal analysis of the crystallization and melting behavior of lipid matrices and lipid nanoparticles containing high amounts of lecithin. Int J Pharm. 2005;298:242–254.
   PubMedGoogle Scholar
• Hamdani J, Moës AJ, Amighi K. Physical and thermal characterisation of Precirol® and Compritol® as lipophilic glycerides used for the preparation of controlled-release matrix pellets. Int J Pharm. 2003;260:47–57.
   PubMed Web of Science ®Google Scholar
• Jores K, Mehnert W, Mäder K. Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: a nuclear magnetic resonance and electron spin resonance study. Pharm Res. 2003;20:1274–1283.
   PubMed Web of Science ®Google Scholar
• Friedrich I, Müller-Goymann CC. Characterization of solidified reverse micellar solutions (SRMS) and production development of SRMS-based nanosuspensions. Eur J Pharm Biopharm. 2003;56:111–119.
   PubMed Web of Science ®Google Scholar
• Jenning V, Thünemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm. 2000;199:167–177.
   PubMed Web of Science ®Google Scholar